Shanghai, China, 12 September 2022 – Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort® MedBot™”) has been named by MIT Technology Review as one of the “50 Smartest Companies” for 2021 ("MIT TR50"). Mr Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot™, was invited to attend the EmTech China Global Emerging Technology Summit and MIT TR50 Award Ceremony. As the first surgical robotics company to be selected for MIT TR50 after the list was introduced to China, MicroPort® MedBot™ is committed to providing smart robotic surgical total solutions to extend and reshape lives, and to leading the smart transformation of healthcare with its superior robotics and innovation capabilities.
Founded in 1899, MIT Technology Review is a world-renowned, independent media company focused on the newest technologies and their commercial, social and political impacts. This year, the MIT TR50 was guided by the concept of a ‘sustainable future’ and focuses on the innovative power of companies ‘born in China, led by China, and serving China’.
According to Mr Yu Liu: "The most important technological innovation progress achieved by our group in 2021 is the continuous breakthrough in cutting-edge research and industrial integration in the fields of robotics, intelligent control, sensing and information, as well as the promotion of several innovative surgical robotic products in registered clinical studies and completing such studies. The advantage of MicroPort® MedBot™ lies in that it has mastered the whole chain of underlying technologies, formed a comprehensive surgical robotics technology innovation platform, and has strong product extension and innovation capabilities. We have become the only innovative company in the world with intelligent solutions for five major surgical robotics specialty products. We will further pioneer innovation, accelerate the R&D and industrialization process, lead the maturation and development of robotic surgery, shape the era of robotic intelligent surgery, and realize our vision to 'let there be no difficult surgeries in the world'".
About MicroPort® MedBot™
Founded in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort® MedBot™”, stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, electrical engineering, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of super intelligent surgery.
More information is available at www.medbotsurgical.com.